Trial Profile
Intervention study of Istradefylline for the Treatment of Abnormal Posture in Patients with Parkinson's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2022
Price :
$35
*
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 15 Jan 2022 Primary endpoint has been met. (Change in the total UDRS score before and after administration of istradefylline), as per Results published in the Journal of the Neurological Sciences
- 15 Jan 2022 Results published in the Journal of the Neurological Sciences
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.